767282-94-0

Usage

Uses

Used in Pharmaceutical Synthesis:
(S)-3-AMINO-3-(2-NAPHTHYL)-PROPIONIC ACID is used as a key intermediate in the synthesis of various pharmaceuticals due to its distinctive structural features. Its ability to be incorporated into the molecular structures of drugs enhances the development of novel therapeutic agents.
Used in Medicinal Chemistry Research:
In the realm of medicinal chemistry, (S)-3-AMINO-3-(2-NAPHTHYL)-PROPIONIC ACID serves as an important compound for research. Its unique properties allow scientists to investigate its interactions with biological targets, potentially leading to the discovery of new drugs and treatment methods.
Used in Drug Development:
(S)-3-AMINO-3-(2-NAPHTHYL)-PROPIONIC ACID is utilized in drug development for its potential therapeutic applications. Its precise chemical structure and properties make it a promising candidate for the treatment of various diseases and conditions, contributing to advancements in healthcare.
Used in Organic Compound Synthesis:
Beyond its pharmaceutical applications, (S)-3-AMINO-3-(2-NAPHTHYL)-PROPIONIC ACID is also used in the synthesis of organic compounds. Its versatility in chemical reactions facilitates the creation of new organic molecules with potential applications in various industries.

Upstream product

• 51557-26-7 3-(2-naphthyl)acrylic acid 
• 141-82-2 malonic acid 
• 66-99-9 β-naphthaldehyde 
• 129042-57-5 3-amino-3-(2-naphthyl)propionic acid 

Downstream Products

• 767282-94-0 (R)-3-amino-3-(2-naphthyl)propanoic acid 

Relevant academic research and scientific papers

Synthesis, molecular docking and biological evaluation of novel phthaloyl derivatives of 3-amino-3-aryl propionic acids as inhibitors of Trypanosoma cruzi trans-sialidase

In the last two decades, trans-sialidase of Trypanosoma cruzi (TcTS) has been an important pharmacological target for developing new anti-Chagas agents. In a continuous effort to discover new potential TcTS inhibitors, 3-amino-3-arylpropionic acid derivatives (series A) and novel phthaloyl derivatives (series B, C and D) were synthesized and molecular docking, TcTS enzyme inhibition and determination of trypanocidal activity were carried out. From four series obtained, compound D-11 had the highest binding affinity value (?11.1 kcal/mol) compared to reference DANA (?7.8 kcal/mol), a natural ligand for TS enzyme. Furthermore, the 3D and 2D interactions analysis of compound D-11 showed a hydrogen bond, π-π stacking, π-anion, hydrophobic and Van der Waals forces with all important amino acid residues (Arg35, Arg245, Arg314, Tyr119, Trp312, Tyr342, Glu230 and Asp59) on the active site of TcTS. Additionally, D-11 showed the highest TcTS enzyme inhibition (86.9% ± 5) by high-performance ion exchange chromatography (HPAEC). Finally, D-11 showed better trypanocidal activity than the reference drugs nifurtimox and benznidazole with an equal % lysis (63 ± 4 and 65 ± 2 at 10 μg/mL) and LC50 value (52.70 ± 2.70 μM and 46.19 ± 2.36 μM) on NINOA and INC-5 strains, respectively. Therefore, D-11 is a small-molecule with potent TcTS inhibition and a strong trypanocidal effect that could help in the development of new anti-Chagas agents.

Synthesis method of (R)-3-amino-3(2-naphthyl)propionic acid

The invention relates to a synthesis method of (R)-3-amino-3(2-naphthyl)propionic acid and mainly aims to solve the technical problem that a method for industrial synthesis of optically pure (R)-3-amino-3(2-naphthyl)propionic acid is unavailable at present. The synthesis method comprises the following three steps: (1) esterification of (R, S)-3-amino-3(2-naphthyl)propionic acid; (2) chiral resolution on the (R, S)-3-amino-3(2-naphthyl)ethyl propionate by using lipase (Lipase PS'Amano'SD); (3) hydrolysis of the (R)-3-amino-3(2-naphthyl)ethyl propionate to obtain final product.

Ruthenium-catalyzed asymmetric epoxidation of olefins using H 2O2, part I: Synthesis of new chiral N,N,N,-tridentate pybox and pyboxazine ligands and their ruthenium complexes

The synthesis of chiral tridentate N,N,N-pyridine-2.6-bisoxazolines 3 (pyhox ligands) and N,N,N-pyridine-2.6-bisoxazines 4 (pyboxazine ligands) is described in detail. These novel ligands constitute a useful tool-box for the application in asymmetric catalysis. Compounds 3 and 4 are conveniently prepared by cyclization of enantiomerically pure α- or β-amino al cohols with dimethyl pyridine-2,6-dicarboximidate. The corresponding ruthenium complexes are efficient asymmetric epoxidation catalysts and have been prepared in good yield and fully char acterized by spectroscopic means. Four of these ruthenium complexes have been characterized by X-ray crystallography. For the first time the molecular structure of a pyboxazine complex (2,6-bis-[(4S)-4-phenyl-5,6- dihydro-4H-[1,3]oxazinyl]pyridine)(pyridine-2,6-dicarboxylate)ruthenium (S)-2aa, is presented.

Novel malonamide derivatives as αvβ3 antagonists. Syntheses and evaluation of 3-(3-indolin-1-yl-3-oxopropanoyl)aminopropanoic acids on vitronectin interaction with αvβ3

In attempt to find novel integrin of αvβ3 antagonists, we selected SC65811 and its guanidine analogue (1) as lead compounds. Modification of the glycine part of SC65811 led to a new series of malonamide derivatives that exhibited αvβ3 inhibitory activity. Among them, (R,S)-3-{3-[6-(3-benzylureido)indolin-1-yl]-3-oxopropanoylamino}-3- (pyridin-3-yl)propanoic acid (43a) showed not only potent activity with an IC50 value of 3.0 nM but also good selectivity for αvβ3 relative to αIIbβ3, α5β1, and αvβ5 with IC50 values of 19000, 11000, and 14 nM, respectively. Furthermore, optimization of 43a led to the most potent αvβ3 antagonist, (R,S)-3-(3-{6-[(4,5-dihydro-1H-imidazol-2-yl)aminoindolin-1-yl}- 3-oxopropanoylamino)-3-(quinolin-3-yl)propanoic acid (431) with an IC50 value of 0.42 nM. The synthesis and the structure-activity relationships of these malonamide derivatives are presented.

META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS

The present invention relates to a class of compounds represented by the Formula Ior a pharmaceutically acceptable salt thereof, whereinA ispharmaceutical compositions thereof and methods of using such compounds and compositions as alphavbeta3 antagonists.

Substituted aryl ureas as high potency sweeteners

Substituted ureas and thioureas are disclosed for use as high potency sweeteners.